Stock Price
P/E Ratio
Volume Traded Today
Dividend
52 Week High/low
AIM ImmunoTech Inc Market Cap
The AIM ImmunoTech Inc (AIM) share price is expected to increase by 1204.35% over the next year. This is based on calculating the average 12-month share price estimate provided by 2 stock analysts who have covered AIM. Price targets range from $1 at the low end to $5 at the high end. The current analyst consensus for AIM is a buy. Please note analyst price targets are not guaranteed and could be missed completely.
About 2 Wall Street analysts have assignedAIM 2 buy ratings, 0 hold ratings, and 0 sell ratings. This means that analysts expect AIM ImmunoTech Inc to buy. Keep in mind that these ratings are typically refreshed every quarter, underscoring the importance of conducting your own research on AIM. Don't forget to include both technical and fundamental analysis, as well as staying informed on news that could influence these ratings, in your due diligence.
These are the latest 20 analyst ratings of AIM.
|
Analyst/Firm |
Rating |
Price Target |
Change |
Date |
|---|---|---|---|---|
| Jason McCarthy Maxim Group | Buy | $1 | Maintains | Oct 22, 2024 |
| Edward Woo Ascendiant Capital | Buy | $5 | Maintains | Sep 3, 2024 |
Maxim Group | Buy | Upgrade | Oct 10, 2019 |
When did it IPO
N/A
Staff Count
26
Country
United States
Sector/Industry
Healthcare/Biotechnology
CEO
Mr. Thomas K. Equels Esq., J.D., M.S.
Market Cap
$14.7M
In 2023, AIM generated $0 in revenue, which was a increase of 0.00% from the previous year. This can be seen as a signal that AIM's business is growing, and its share price could be worth more in the future. However, if the company grows faster (or slower) than expected, this could also have a major impact on the future share price.
Revenue From 2020
Revenue From 2021
Revenue From 2022
Revenue From 2023
Mon, 25 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - AIM ImmunoTech Inc. has scheduled its 2024 Annual Meeting for December 17, 2024, highlighting its strategy to enhance value through clinical development in critical areas.
Why It Matters - AIM ImmunoTech's focus on clinical development in unmet medical needs signals potential growth and innovation, which may enhance shareholder value and attract investor interest.
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - AIM ImmunoTech Inc. has implemented a Cash Conservation Plan to enhance its financial stability and support progress in achieving important clinical milestones.
Why It Matters - AIM ImmunoTech's Cash Conservation Plan signals a strategic focus on preserving funds to support clinical milestones, potentially enhancing its growth prospects and investor confidence.
Wed, 27 Nov 2024
Sentiment - NEUTRAL
Source - Business Wire
Summary - AIM ImmunoTech Inc. refuted claims from activist investors seeking to take over its Board of Directors at the Annual Meeting set for December 17, 2024.
Why It Matters - AIM ImmunoTech's rebuttal to activist investors highlights potential governance instability, which can affect stock performance and investor confidence leading to volatility around the upcoming meeting.
Tue, 19 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - AIM ImmunoTech Inc. announced the publication of data from a Phase 1 study on Ampligen® in early-stage triple-negative breast cancer, reported in The Journal for ImmunoTherapy of Cancer.
Why It Matters - The publication of AIM ImmunoTech's study results on Ampligen® could boost investor confidence, potentially leading to increased stock demand and market valuation for the company.
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - Seeking Alpha
Summary - AIM ImmunoTech Inc. held its Q3 2024 earnings call on November 15, 2024, featuring CEO Thomas Equels and Scientific Officer Christopher McAleer.
Why It Matters - AIM ImmunoTech's Q3 2024 earnings call may reveal insights on financial performance and strategic direction, impacting stock valuation and investor sentiment.
Fri, 15 Nov 2024
Sentiment - NEUTRAL
Source - GlobeNewsWire
Summary - Ampligen® clinical development is advancing, focusing on high-need areas like pancreatic cancer, which may present significant investment opportunities.
Why It Matters - Successful clinical development of Ampligen® in pancreatic cancer could lead to significant market opportunity and revenue growth, influencing stock performance and investment decisions.
The information that Ticker Nerd provides is general in nature as it has been prepared without taking account of your objectives, financial situation or needs. It is not intended as legal, financial or investment advice and should not be construed or relied on as such. Ticker Nerd is for information purposes only. Ticker Nerd is not responsible for any damages or losses that may occur as a result of reliance on this information. Before making any commitment of a legal or financial nature you should seek advice from a qualified and registered legal practitioner or financial or investment adviser. All content, group, messaging, tweets, newsletter, article, and email created by Ticker Nerd is intended for educational and information purposes only, is not financial, investment, legal or tax advice, and is a restatement, summary or extract of other data and research reports that are widely distributed from sources such as, but not limited to, Bloomberg, Market Watch, Wall Street Journal, Google Finance, and Yahoo Finance. Ticker Nerd is not a registered financial, investment, legal or tax advisor and is not liable for any financial loss you may incur acting on any information provided by Ticker Nerd. By registering, you agree not to hold Ticker Nerd liable at any time or under any circumstances for your decisions, actions, or results.
